Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Decrease in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 22,618 shares, a decline of 85.8% from the October 15th total of 159,295 shares. Based on an average trading volume of 48,253 shares, the short-interest ratio is presently 0.5 days. Currently, 1.7% of the company’s shares are short sold.

Institutional Trading of Enlivex Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ENLV. WINTON GROUP Ltd acquired a new position in Enlivex Therapeutics in the second quarter valued at about $55,000. Bank of America Corp DE increased its position in shares of Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after acquiring an additional 45,303 shares during the last quarter. Finally, Susquehanna International Group LLP raised its stake in shares of Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares during the period. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ENLV shares. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Finally, Zacks Research lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enlivex Therapeutics has a consensus rating of “Hold” and an average price target of $4,800.00.

Enlivex Therapeutics Trading Down 4.4%

ENLV stock traded down $0.06 during midday trading on Friday, hitting $1.19. 22,263 shares of the company’s stock were exchanged, compared to its average volume of 24,579. Enlivex Therapeutics has a 1-year low of $1.18 and a 1-year high of $434.40. The stock has a market capitalization of $1.82 million, a PE ratio of -0.01 and a beta of 1.63. The business has a 50-day simple moving average of $6.75 and a two-hundred day simple moving average of $128.80.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.